OncoCyte Statistics

Total Valuation

OncoCyte has a market cap or net worth of GBP 26.79 million. The enterprise value is 27.30 million.

Market Cap	26.79M
Enterprise Value	27.30M

Important Dates

The next estimated earnings date is Friday, April 4, 2025.

Earnings Date	Apr 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+52.57%
Shares Change (QoQ)	+6.56%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	6.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.05, with an EV/FCF ratio of -1.80.

EV / Earnings	-0.84
EV / Sales	47.43
EV / EBITDA	0.05
EV / EBIT	n/a
EV / FCF	-1.80

Financial Position

The company has a current ratio of 0.53, with a Debt / Equity ratio of 0.41.

Current Ratio	0.53
Quick Ratio	0.39
Debt / Equity	0.41
Debt / EBITDA	0.01
Debt / FCF	-0.20
Interest Coverage	-341.52

Financial Efficiency

Return on equity (ROE) is -165.32% and return on invested capital (ROIC) is -48.27%.

Return on Equity (ROE)	-165.32%
Return on Assets (ROA)	-18.84%
Return on Capital (ROIC)	-48.27%
Revenue Per Employee	11,755
Profits Per Employee	-723,054
Employee Count	46
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.25% in the last 52 weeks. The beta is 1.01, so OncoCyte's price volatility has been similar to the market average.

Beta (5Y)	1.01
52-Week Price Change	-42.25%
50-Day Moving Average	2.69
200-Day Moving Average	22.52
Relative Strength Index (RSI)	37.77
Average Volume (20 Days)	2,691

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.89

Income Statement

In the last 12 months, OncoCyte had revenue of GBP 528,985 and -32.54 million in losses. Loss per share was -3.02.

Revenue	528,985
Gross Profit	86,548
Operating Income	-17.07M
Pretax Income	-32.19M
Net Income	-32.54M
EBITDA	-16.08M
EBIT	-17.07M
Loss Per Share	-3.02

Full Income Statement

Balance Sheet

The company has 2.51 million in cash and 2.98 million in debt, giving a net cash position of -468,551.

Cash & Cash Equivalents	2.51M
Total Debt	2.98M
Net Cash	-468,551
Net Cash Per Share	n/a
Equity (Book Value)	7.25M
Book Value Per Share	0.54
Working Capital	-3.21M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.76 million and capital expenditures -422,293, giving a free cash flow of -15.18 million.

Operating Cash Flow	-14.76M
Capital Expenditures	-422,293
Free Cash Flow	-15.18M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	16.36%
Operating Margin	-3,227.36%
Pretax Margin	-6,085.19%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.57%
Shareholder Yield	-52.57%
Earnings Yield	-121.44%
FCF Yield	-56.67%

Stock Splits

The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jul 25, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

OncoCyte has an Altman Z-Score of -7.15. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.15
Piotroski F-Score	n/a